Sofosbuvir & Ledipasvir Tablets

Form: Tablet

Strength: 90 mg Ledipasvir / 400 mg Sofosbuvir

Reference Brands: Harvoni® (EU & US)

Category: Hepatitis

Sofosbuvir & Ledipasvir Tablets are a fixed-dose oral antiviral combination used to treat chronic Hepatitis C virus (HCV) infection. Marketed globally under the brand name Harvoni®, this potent direct-acting antiviral (DAA) therapy combines 90 mg Ledipasvir and 400 mg Sofosbuvir to inhibit viral replication. Approved by the US FDA and EMA, it offers a highly effective, once-daily regimen with excellent safety and tolerability profiles. Essential for pharma B2B suppliers and healthcare providers in the EU and US, Sofosbuvir & Ledipasvir supports global efforts to eliminate Hepatitis C through curative treatment options.